“We are pleased to have signed the first chemical countermeasure contract that BARDA has awarded."
Charlotte, NC (PRWEB) September 12, 2011
Countervail Corporation announces the award of a $5.3 million contract from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) to support the advanced development over the next 16 months of the company’s drug, AverTox™, as a chemical countermeasure to toxic nerve agent exposure. The contract contains options for further development that when fully exercised is valued at $24.3 million.
“We are pleased to have signed the first chemical countermeasure contract that BARDA has awarded. Our overall goal is to develop a safe, easy to administer, cost effective, and neuroprotective medical countermeasure that will effectively treat the downwind and worried well populations following a nerve agent attack.” says Bill Basinger, Countervail’s CEO and President.
Countervail Corporation is a US based company formed in June 2007 and is focused on the protection of our military and civilian populations from chemical and biological threats.
This project has been funded in whole or in part with Federal funds from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No: HHSO100201100030C.
For Additional information please contact:
Bill Basinger 704-688-5520